Aurobindo Pharma USA, Inc has received approval from the US Federal Trade Commission (FTC) to proceed with the acquisition of Lannett Company LLC. The transaction, valued at USD 250 million, a cash-free, debt-free basis and inclusive of normalised working capital, is expected to close before the end of June 2026.

Lannett, a Pennsylvania-based generic pharmaceutical company, specialises in the development and commercialisation of a diversified portfolio of complex, non-opioid controlled substances. The acquisition will significantly expand Aurobindo USA’s product offering in this segment while adding a US-based manufacturing facility to its network.

Lannett’s manufacturing site in Seymour, Indiana, has the capacity to scale production to approximately 4 billion doses annually, strengthening Aurobindo USA’s domestic manufacturing footprint. This enhanced capacity aligns with US policy priorities aimed at improving supply chain resilience and increasing domestic pharmaceutical production.

Swami S Iyer, Chief Executive Officer (CEO), Aurobindo Pharma USA, said, “This acquisition represents a highly compelling strategic and financial opportunity for Aurobindo USA. It accelerates our revenue growth, strengthens our US-based manufacturing capabilities, and enhances our position in complex, non-opioid controlled substances. We are confident it will deliver immediate earnings accretion while creating long-term value for our shareholders through operational synergies and pipeline expansion. We are pleased to welcome the Lannett team and look forward to leveraging our combined strengths to expand and ensure reliable access to critical medications for patients.”

The transaction is expected to be immediately accretive to Aurobindo Group’s earnings per share. In addition to near-term financial benefits, the acquisition is anticipated to generate meaningful cost efficiencies, SG&A synergies, and operational integration advantages. It will also enhance the company’s portfolio with a differentiated pipeline of complex generics and controlled substances, supporting sustainable long-term growth.

Tim Crew, Chief Executive Officer (CEO), Lannett Company, said, “We are delighted to be joining forces with Aurobindo. As one of the nation’s oldest generic pharmaceutical companies, Lannett has a proud history of helping patients access affordable medicines. Aurobindo’s market reach and resources will help make our portfolio of medicines even more affordable and accessible for patients everywhere. Our board and owners extend their sincere appreciation to the outstanding teams at both companies whose professionalism, commitment, and hard work have successfully brought us to this important moment. We look forward to building on all that has come before as we begin a bright and exciting next chapter.”